IGM Biosciences Inc
IGMS1.270USD
0.000
Close 12/12, 16:00（ET）Quotes delayed by 15 min
76.45MMarket Cap
LossP/E TTM
More Details of IGM Biosciences Inc Company
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
IGM Biosciences Inc Info
Ticker SymbolIGMS
Company nameIGM Biosciences Inc
IPO dateSep 18, 2019
CEODr. Mary Beth Harler, M.D.
Number of employees149
Security typeOrdinary Share
Fiscal year-endSep 18
Address325 E Middlefield Rd
CityMOUNTAIN VIEW
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94043-4003
Phone16509657873
Websitehttps://igmbio.com/
Ticker SymbolIGMS
IPO dateSep 18, 2019
CEODr. Mary Beth Harler, M.D.
Company Executives of IGM Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas Wei
Mr. Thomas Wei
Chief Business Officer
Chief Business Officer
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Michael Hearne
Mr. Michael Hearne
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Ryan Cole
Mr. Ryan Cole
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Stew Kroll
Mr. Stew Kroll
Chief Development Officer
Chief Development Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas Wei
Mr. Thomas Wei
Chief Business Officer
Chief Business Officer
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Michael Hearne
Mr. Michael Hearne
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Ryan Cole
Mr. Ryan Cole
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Stew Kroll
Mr. Stew Kroll
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
143.62M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Aug 21
Updated: Thu, Aug 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Invus Public Equities Advisors, LLC
8.90%
Glazer Capital, LLC
6.93%
Sanofi SA
3.93%
Goldman Sachs & Company, Inc.
2.34%
The Vanguard Group, Inc.
2.10%
Other
75.81%
Shareholders
Shareholders
Proportion
Invus Public Equities Advisors, LLC
8.90%
Glazer Capital, LLC
6.93%
Sanofi SA
3.93%
Goldman Sachs & Company, Inc.
2.34%
The Vanguard Group, Inc.
2.10%
Other
75.81%
Shareholder Types
Shareholders
Proportion
Individual Investor
2.60%
Investment Advisor
0.14%
Other
97.26%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
243
28.75M
78.60%
-9.33M
2025Q1
258
30.98M
89.26%
-9.33M
2024Q4
261
34.20M
100.37%
-4.65M
2024Q3
262
33.88M
99.73%
-5.05M
2024Q2
269
34.16M
101.16%
-4.19M
2024Q1
277
34.60M
103.20%
-3.37M
2023Q4
277
33.51M
100.77%
-4.17M
2023Q3
286
34.23M
103.22%
-3.29M
2023Q2
291
34.31M
107.60%
+1.63M
2023Q1
295
29.58M
100.36%
-4.78M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Invus Public Equities Advisors, LLC
--
0%
--
--
Glazer Capital, LLC
--
0%
+2.53M
-100.00%
Sanofi SA
--
0%
--
--
Goldman Sachs & Company, Inc.
--
0%
+80.14K
-100.00%
The Vanguard Group, Inc.
--
0%
-108.42K
-100.00%
Behrens (M Kathleen)
--
0%
-22.22K
-100.00%
BlackRock Institutional Trust Company, N.A.
--
0%
-579.80K
-100.00%
Millennium Management LLC
--
0%
+275.11K
-100.00%
Schwarzer Fred M
--
0%
+34.30K
-100.00%
Geode Capital Management, L.L.C.
--
0%
-212.39K
-100.00%
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Global X Russell 2000 ETF
0%
Fidelity MSCI Health Care Index ETF
0%
iShares Russell 3000 ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 Covered Call ETF
0%
Avantis US Small Cap Equity ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0%
Fidelity MSCI Health Care Index ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of IGM Biosciences Inc?
The top five shareholders of IGM Biosciences Inc are:
Invus Public Equities Advisors, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Glazer Capital, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Sanofi SA holds 0.00 shares, accounting for 0.00% of the total shares.
Goldman Sachs & Company, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
The Vanguard Group, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
Invus Public Equities Advisors, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Glazer Capital, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Sanofi SA holds 0.00 shares, accounting for 0.00% of the total shares.
Goldman Sachs & Company, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
The Vanguard Group, Inc. holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of IGM Biosciences Inc?
The top three shareholder types of IGM Biosciences Inc are:
Invus Public Equities Advisors, LLC
Glazer Capital, LLC
Sanofi SA
Invus Public Equities Advisors, LLC
Glazer Capital, LLC
Sanofi SA
How many institutions hold shares of IGM Biosciences Inc (IGMS)?
As of 2025Q2, 243 institutions hold shares of IGM Biosciences Inc, with a combined market value of approximately 28.75M, accounting for 78.60% of the total shares. Compared to 2025Q1, institutional shareholding has increased by -10.66%.
What is the biggest source of revenue for IGM Biosciences Inc?
In FY2025Q2, the -- business generated the highest revenue for IGM Biosciences Inc, amounting to -- and accounting for --% of total revenue.
